Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Semaglutide 2.4 mg Induces Weight Loss and Improves Body Composition Across Age Groups in Adults With Overweight or Obesity: Post-Hoc Analysis of the STEP 1 Trial

Dror Dicker1; Rachel L. Batterham2; Juan P. Frias3; Luc F. Van Gaal4; Camilla Jensen5; David C.W. Lau6; Peter Nørkjær Laursen5; Barbara M. McGowan MD PhD7; Kristian Kandler MD PhD5; Frank L. Greenway MD8;
1Internal Medicine Department & Obesity Clinic, Hasharon Hospital-Rabin Medical Center, Petach-Tikva, Sackler; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2University College London Centre for Obesity Research, Division of Medicine, University College London and National Institute of Health Research, UCLH Biomedical Research Centre and Centre for Weight Management and Metabolic Surgery, UCLH, London, UK; 3National Research Institute, Los Angeles, CA, USA; 4Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, University of Antwerp, Belgium; 5Novo Nordisk A/S, Søborg, Denmark; 6Julia McFarlane Diabetes Research Centre and Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada; 7Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK; 8Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.;